Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy
Abstract Purpose To define the efficacy of standard androgen deprivation therapy (ADT) in the treatment of metastatic prostate cancer (PCa). Materials and methods Fifty patients with mean age of 70.48 ± 9.95 years old (range 52–87) who had metastatic PCa and received ADT between 2014 and 2019 were r...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-01-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12957-020-02111-3 |
| _version_ | 1818580093896753152 |
|---|---|
| author | Mahmoud Mustafa Honood Abu Rass Mothafr Yahya Khaleel Hamdan Yazan Eiss |
| author_facet | Mahmoud Mustafa Honood Abu Rass Mothafr Yahya Khaleel Hamdan Yazan Eiss |
| author_sort | Mahmoud Mustafa |
| collection | DOAJ |
| description | Abstract Purpose To define the efficacy of standard androgen deprivation therapy (ADT) in the treatment of metastatic prostate cancer (PCa). Materials and methods Fifty patients with mean age of 70.48 ± 9.95 years old (range 52–87) who had metastatic PCa and received ADT between 2014 and 2019 were retrospectively evaluated. Median values of pre-therapeutic PSA and Gleason scores were 50 ng/ml (range 8–1201) and 8 (range 6–9), respectively. All patients received luteinizing hormone-releasing hormone (LHRH) analogue and anti-androgen. The patients were evaluated in terms of age, pre-therapeutic PSA serum levels, Gleason scores, presence of metastasis, number and percentage of cores involved, nadir PSA, time to nadir PSA, duration of ADT, and PSA at last follow-up. Multivariate analysis was used to define the factors which have impact on ADT response. The mean follow-up period was 13.87 ± 7.78 months, (range 2–32). Results All patients showed reduction in serum PSA level after initiation of ADT, and the median value of nadir PSA was 1.12 ng/ml (range 0.02–50). The mean value of time to nadir PSA was 3.85 ± 1.57 months (range 2–7). The median value of PSA at last follow-up was 2 ng/ml (range 0.02–50.21). Multi-variant analysis showed that nadir PSA have a significant correlation with pre-therapeutic PSA, PSA at last follow-up, age, and Gleason scores (p < .05). Conclusion Standard ADT is a feasible option in the treatment of metastatic PCa. Gleason scores, age, pre-therapeutic PSA, and PSA at last follow-up have significant impact on outcomes of ADT. Further studies of high number of patients with long-term follow-up including other chemo-hormonal therapy and androgen receptor blockers should be carried out to confirm and improve efficacy of ADT. |
| first_indexed | 2024-12-16T07:12:07Z |
| format | Article |
| id | doaj.art-33de7171d4064b91997e7f2ea51ae4a1 |
| institution | Directory Open Access Journal |
| issn | 1477-7819 |
| language | English |
| last_indexed | 2024-12-16T07:12:07Z |
| publishDate | 2021-01-01 |
| publisher | BMC |
| record_format | Article |
| series | World Journal of Surgical Oncology |
| spelling | doaj.art-33de7171d4064b91997e7f2ea51ae4a12022-12-21T22:39:52ZengBMCWorld Journal of Surgical Oncology1477-78192021-01-011911610.1186/s12957-020-02111-3Primary metastatic prostate cancer between prognosis or adequate/proper medical therapyMahmoud Mustafa0Honood Abu Rass1Mothafr Yahya2Khaleel Hamdan3Yazan Eiss4Urology Department, Faculty of Medicine and Health Science, An-Najah National UniversityPathology Department, Faculty of Medicine and Health Science, An-Najah National UniversityUrology Department, Faculty of Medicine and Health Science, An-Najah National UniversityUrology Department, Faculty of Medicine and Health Science, An-Najah National UniversityUrology Department, Faculty of Medicine and Health Science, An-Najah National UniversityAbstract Purpose To define the efficacy of standard androgen deprivation therapy (ADT) in the treatment of metastatic prostate cancer (PCa). Materials and methods Fifty patients with mean age of 70.48 ± 9.95 years old (range 52–87) who had metastatic PCa and received ADT between 2014 and 2019 were retrospectively evaluated. Median values of pre-therapeutic PSA and Gleason scores were 50 ng/ml (range 8–1201) and 8 (range 6–9), respectively. All patients received luteinizing hormone-releasing hormone (LHRH) analogue and anti-androgen. The patients were evaluated in terms of age, pre-therapeutic PSA serum levels, Gleason scores, presence of metastasis, number and percentage of cores involved, nadir PSA, time to nadir PSA, duration of ADT, and PSA at last follow-up. Multivariate analysis was used to define the factors which have impact on ADT response. The mean follow-up period was 13.87 ± 7.78 months, (range 2–32). Results All patients showed reduction in serum PSA level after initiation of ADT, and the median value of nadir PSA was 1.12 ng/ml (range 0.02–50). The mean value of time to nadir PSA was 3.85 ± 1.57 months (range 2–7). The median value of PSA at last follow-up was 2 ng/ml (range 0.02–50.21). Multi-variant analysis showed that nadir PSA have a significant correlation with pre-therapeutic PSA, PSA at last follow-up, age, and Gleason scores (p < .05). Conclusion Standard ADT is a feasible option in the treatment of metastatic PCa. Gleason scores, age, pre-therapeutic PSA, and PSA at last follow-up have significant impact on outcomes of ADT. Further studies of high number of patients with long-term follow-up including other chemo-hormonal therapy and androgen receptor blockers should be carried out to confirm and improve efficacy of ADT.https://doi.org/10.1186/s12957-020-02111-3ProstateProstate cancerHormonal therapy |
| spellingShingle | Mahmoud Mustafa Honood Abu Rass Mothafr Yahya Khaleel Hamdan Yazan Eiss Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy World Journal of Surgical Oncology Prostate Prostate cancer Hormonal therapy |
| title | Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy |
| title_full | Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy |
| title_fullStr | Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy |
| title_full_unstemmed | Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy |
| title_short | Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy |
| title_sort | primary metastatic prostate cancer between prognosis or adequate proper medical therapy |
| topic | Prostate Prostate cancer Hormonal therapy |
| url | https://doi.org/10.1186/s12957-020-02111-3 |
| work_keys_str_mv | AT mahmoudmustafa primarymetastaticprostatecancerbetweenprognosisoradequatepropermedicaltherapy AT honoodaburass primarymetastaticprostatecancerbetweenprognosisoradequatepropermedicaltherapy AT mothafryahya primarymetastaticprostatecancerbetweenprognosisoradequatepropermedicaltherapy AT khaleelhamdan primarymetastaticprostatecancerbetweenprognosisoradequatepropermedicaltherapy AT yazaneiss primarymetastaticprostatecancerbetweenprognosisoradequatepropermedicaltherapy |